/ /

Michelle Dalton, ELS
Managing conjunctival pigmented lesions
Knowing how to recognize and manage the various forms of conjunctival pigmented lesions can literally mean the difference between life and death in some cases.
FDA approves tocilizumab, first therapy for GCA
The FDA recently granted regulatory approval for tocilizumab (Actemra, Genentech), the first approved therapy for the treatment of adults with giant cell arteritis.
Pros and cons of compounded pharmaceuticals
Compounded pharmaceuticals have been used for decades, but does that mean they are reliable and safe? “Absolutely,” asserted Dante Pieramici, MD. “The literature disagrees,” said Julia Haller, MD.
Is DSAEK still the gold standard over DMEK for endothelial disease?
Multiple advantages of DSAEK include successful outcomes, less risk of graft tears, and alternative options for complex patients with comorbidities. Overall, the procedure offers an aspect of simplicity in that it also has less restrictions for donor age criteria compared with DMEK.
Researchers find arthritis therapy ‘effective’ for noninfectious uveitis
Multiple intravenous administrations of tocilizumab for noninfectious uveitis can be effective in improving visual acuity and reducing vitreous haze.
Adalimumab promising in treating JIA-associated uveitis, study finds
Results from the Study Assessing double-masKed Uveitis tREAtrement (SAKURA) program support the efficacy and safety of intravitreal sirolimus 440 mcg (Opsiria, Santen) for treating noninfectious uveitis of the posterior segment, said Pauline T. Merrill, MD.
‘Ideal’ disease control leads to better nAMD outcomes
Neovascular age-related macular degeneration (nAMD) is well-known as a heterogeneous disease with variable natural history and variable treatment response, said Carl D. Regillo, MD, FACS. Many patients do well without monthly treatment as noted in HARBOR PRN arms.
Treat-and-extend may lead to better AMD results
Treating neovascular age-related macular degeneration (nAMD) patients with anti-vascular endothelial growth factor (anti-VEGF) ranibizumab (Lucentis, Genentech) on a monthly regimen has produced “great results” in clinical trials, said Prof. Mark C. Gillies, MBBS, PhD. “But what happens after that and what happens in real world practice?”
2016 brings retinal imaging into starring role
This has been the year of optical coherence tomography (OCT) angiography, numerous retina specialists said. Commercially available systems are available from Carl Zeiss Meditec, Heidelberg Engineering, and Optovue provide a noninvasive way to image retinal vasculature and confirm clinicians’ diagnoses of abnormalities.
Drug therapies moving beyond anti-VEGFs
Pharmacologic activity in the retina realm continues to hold much excitement for new therapies to treat retinal disorders.

Poll

View Results